Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.
about
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trialEffect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells.Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
P2860
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Imatinib mesylate (Glivec) pre ...... iladelphia-positive leukemias.
@en
type
label
Imatinib mesylate (Glivec) pre ...... iladelphia-positive leukemias.
@en
prefLabel
Imatinib mesylate (Glivec) pre ...... iladelphia-positive leukemias.
@en
P2093
P2860
P356
P1476
Imatinib mesylate (Glivec) pre ...... iladelphia-positive leukemias.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704687
P407
P577
2004-11-01T00:00:00Z
P5875
P6179
1002882330